Literature DB >> 10962308

Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CAPSURE database.

G D Grossfeld1, J J Chang, J M Broering, D P Miller, J Yu, S C Flanders, P R Carroll.   

Abstract

OBJECTIVES: To determine whether more complete sampling of the radical prostatectomy (RP) specimen better predicts outcome after surgery.
METHODS: We reviewed pathology reports from 1383 patients enrolled in CaPSURE (a longitudinal registry of patients with prostate cancer) who underwent RP. Specimens were considered step-sectioned only if the entire specimen was submitted for analysis and if sections were taken at 0.5-cm intervals or less. Otherwise, specimens were considered non-step-sectioned. Pathologic stage, Gleason score, surgical margin status, and outcome were compared between groups. Prostate-specific antigen (PSA) recurrence was defined as a PSA level of 0.2 ng/mL or greater on two consecutive occasions after RP. Secondary cancer treatment consisted of radiation or androgen deprivation after RP. Adjuvant treatments occurred within 6 months of RP, and nonadjuvant treatments occurred more than 6 months after RP. Kaplan-Meier event rates of PSA recurrence and secondary treatment were calculated for patients in the step-sectioned and non-step-sectioned groups.
RESULTS: No significant differences were found between patients in the step-sectioned and non-step-sectioned groups with respect to pathologic tumor stage, prostatectomy Gleason score, or margin status. Patients in whom step-sectioning was performed had a lower serum PSA at diagnosis than patients in the non-step-sectioned group. When examining all patients, no differences were observed in the use of secondary treatments or PSA recurrence based on the method of pathologic analysis. However, patients with negative margins in whom step-sectioning was performed exhibited significantly lower secondary nonadjuvant treatment use and appeared to have a lower risk of PSA recurrence than similar patients in the non-step-sectioned group.
CONCLUSIONS: These data suggest that more complete pathologic analysis of the surgical specimen may better predict outcome for some patients undergoing RP. Additional research is warranted to determine whether such differences justify the additional resources necessary to recommend routine step-sectioning.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962308     DOI: 10.1016/s0090-4295(00)00705-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.

Authors:  Raquel Esgueva; Kyung Park; Robert Kim; Naoki Kitabayashi; Christopher E Barbieri; Philip J Dorsey; Cyril Abraham; Samprit Banerjee; Robert A Leung; Ashutosh K Tewari; Stéphane Terry; Maria M Shevchuk; David S Rickman; Mark A Rubin
Journal:  Diagn Mol Pathol       Date:  2012-06

3.  Central quadrant procurement of radical prostatectomy specimens.

Authors:  Carl Morrison; Richard Cheney; Candace S Johnson; Gary Smith; James L Mohler
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

4.  Partial versus complete prostatectomy specimen sampling: prospective non-inferiority study for pT3a tumours and surgical margin involvement.

Authors:  Eelco R P Collette; Michael A den Bakker; Sjoerd O Klaver; André N Vis; Mike Kliffen
Journal:  BMJ Open       Date:  2019-04-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.